Improved antimicrobial host defense in mice following poly-(1,6)-β-D- glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism

Clinical and Vaccine Immunology

Volumn 18, Issue 12, 2011, Pages 2043-2049

  Newsome, Courtni T ^a   Flores, Estefany ^a   Ayala, Alfred ^a   Gregory, Stephen ^a   Reichner, Jonathan S ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAFECTIN; ESTRADIOL; IMPRIME PGG; INTERLEUKIN 10; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BLOOD ANALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HOST RESISTANCE; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEX DIFFERENCE; SINGLE DRUG DOSE; SURVIVAL TIME;

ANIMALS; BACTERIAL INFECTIONS; BACTERIAL LOAD; BETA-GLUCANS; FEMALE; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTERLEUKIN-6; LIVER; MALE; MICE; SEPSIS; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 83455220105     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05202-11     Document Type: Article

References (46)

1. Adams, D. S., et al. 1997. PGG glucan activates NF-kappaB-like and NFIL-6-like transcription factor complexes in a murine monocytic cell line. J. Leukoc. Biol. 62:865-873. (Pubitemid 28015636)
2. Almdahl, S. M., J. Bogwald, J. Hoffman, K. E. Giercksky, and R. Seljelid. 1987. Protection by aminated glucan in experimental endogenous peritonitis. Eur. Surg. Res. 19:78-85. (Pubitemid 17008050)
3. Almdahl, S. M., J. Bogwald, J. Hoffman, and R. Seljelid. 1987. Treatment of experimental peritonitis in rats by transfer of peritoneal mononuclear cells from rats injected with semisoluble aminated glucan. Acta Chir. Scand. 153:535-539.
4. Angus, D. C., et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310. (Pubitemid 32641789)
5. Babineau, T. J., et al. 1994. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. 129:1204-1210. (Pubitemid 24335973)
6. Babineau, T. J., et al. 1994. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 220:601-609.
7. Baker, C. C., I. H. Chaudry, H. O. Gaines, and A. E. Baue. 1983. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335. (Pubitemid 13043132)
8. Bernard, G. R., et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709. (Pubitemid 32204987)
9. Bowers, G. J., M. L. Patchen, T. J. MacVittie, E. F. Hirsch, and M. P. Fink. 1989. Glucan enhances survival in an intraabdominal infection model. J. Surg. Res. 47:183-188. (Pubitemid 19197618)
10. Brown, G. D., and S. Gordon. 2003. Fungal beta-glucans and mammalian immunity. Immunity 19:311-315.
11. Cisneros, R. L., F. C. Gibson III, and A. O. Tzianabos. 1996. Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis. Infect. Immun. 64:2201-2205.
12. Cramer, D. E., et al. 2008. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells 26:1231-1240.
13. Dellinger, E. P., et al. 1999. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch. Surg. 134:977-983. (Pubitemid 29428910)
14. Ebong, S., et al. 1999. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect. Immun. 67:6603-6610.
15. Gawronski, M., J. T. Park, A. S. Magee, and H. Conrad. 1999. Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle X-ray scattering. Biopolymers 50:569-578. (Pubitemid 29503488)
16. Godshall, C. J., M. J. Scott, P. T. Burch, J. C. Peyton, and W. G. Cheadle. 2003. Natural killer cells participate in bacterial clearance during septic peritonitis through interactions with macrophages. Shock 19:144-149.
17. Goodridge, H. S., et al. 2011. Activation of the innate immune receptor dectin-1 upon formation of a 'phagocytic synapse.' Nature 472:471-476.
18. Hwang, T. L., and Y. M. Yang. 2008. Sex differences in response to immunonutrition in sepsis. Nutrition 24:761-766.
19. Knöferl, M. W., M. K. Angele, M. G. Schwacha, K. I. Bland, and I. H. Chaudry. 2002. Preservation of splenic immune functions by female sex hormones after trauma-hemorrhage. Crit. Care Med. 30:888-893. (Pubitemid 34297813)
20. Kournikakis, B., R. Mandeville, P. Brousseau, and G. Ostroff. 2003. Anthrax-protective effects of yeast beta 1,3 glucans. Med. Gen. Med. 5:1.
21. LeBlanc, B. W., J. E. Albina, and J. S. Reichner. 2006. The effect of PGG-beta-glucan on neutrophil chemotaxis in vivo. J. Leukoc. Biol. 79:667-675. (Pubitemid 44835599)
22. Leon, L. R., A. A. White, and M. J. Kluger. 1998. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol. 275:R269-R277.
23. Li, B., et al. 2007. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clin. Immunol. 124:170-181. (Pubitemid 47061522)
24. Liang, J., et al. 1998. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol. 20:595-614. (Pubitemid 28535144)
25. Liu, J., L. Gunn, R. Hansen, and J. Yan. 2009. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp. Mol. Pathol. 86:208-214.
26. Lyuksutova, O. I., et al. 2005. Glucan phosphate treatment attenuates burn-induced inflammation and improves resistance to Pseudomonas aeruginosa burn wound infection. Shock 23:224-232. (Pubitemid 40293821)
27. Marshall, J. C. 2010. Principles of source control in the early management of sepsis. Curr. Infect. Dis. Rep. 12:345-353.
28. Onderdonk, A. B., R. L. Cisneros, P. Hinkson, and G. Ostroff. 1992. Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose glucan in vivo. Infect. Immun. 60:1642-1647.
29. Osuchowski, M. F., K. Welch, J. Siddiqui, and D. G. Remick. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967-1974. (Pubitemid 44092537)
30. Patchen, M. L., et al. 1998. Mobilization of peripheral blood progenitor cells by Betafectin PGG-glucan alone and in combination with granulocyte colony-stimulating factor. Stem Cells 16:208-217. (Pubitemid 28235165)
31. Poutsiaka, D. D., M. Mengozzi, E. Vannier, B. Sinha, and C. A. Dinarello. 1993. Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production. Blood 82:3695-3700.
32. Pretus, H. A., et al. 1991. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J. Pharmacol. Exp. Ther. 257:500-510.
33. Remick, D. G. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170:1435-1444. (Pubitemid 47339289)
34. Remick, D. G., G. Bolgos, S. Copeland, and J. Siddiqui. 2005. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect. Immun. 73:2751-2757. (Pubitemid 40570341)
35. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467.
36. Rice, P. J., et al. 2005. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J. Pharmacol. Exp. Ther. 314:1079-1086. (Pubitemid 41205971)
37. Swan, R., et al. 2007. Polymicrobial sepsis enhances clearance of apoptotic immune cells by splenic macrophages. Surgery 142:253-261. (Pubitemid 47198663)
38. Tzianabos, A. O., F. C. Gibson III, R. L. Cisneros, and D. L. Kasper. 1998. Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators. J. Infect. Dis. 178:200-206. (Pubitemid 28328094)
39. Vyas, D., et al. 2005. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289:R1048-R1053. (Pubitemid 41397053)
40. Wakshull, E., et al. 1999. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology 41:89-107. (Pubitemid 29099822)
41. Walley, K. R., N. W. Lukacs, T. J. Standiford, R. M. Strieter, and S. L. Kunkel. 1996. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect. Immun. 64:4733-4738. (Pubitemid 26357085)
42. Weber, M., et al. 2003. Transcriptional inhibition of interleukin-8 expression in tumor necrosis factor-tolerant cells. J. Biol. Chem. 278:23586-23593. (Pubitemid 36830179)
43. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29:189-201. (Pubitemid 10039498)
44. Williams, D. L., et al. 1999. Inhibiting early activation of tissue nuclear factor-kappa B and nuclear factor interleukin 6 with (1→3)-beta-D-glucan increases long-term survival in polymicrobial sepsis. Surgery 126:54-65. (Pubitemid 29340692)
45. Williams, D. L., et al. 1991. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology 22:139-155.
46. Zellweger, R., et al. 1997. Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit. Care Med. 25:106-110. (Pubitemid 27015048)